October 2008
Worldwide Biotech;Oct2008, Vol. 20 Issue 10, p1
Trade Publication
The article reports on the acceptance by the U.S. Food and Drug Administration (FDA) of data submitted by Bridge Laboratories from its Beijing, China facility on behalf of a U.S. biotechnology client. Bridge's Good Laboratory Practices (GLP) nonhuman primate toxicology study data was submitted in September 2008 as part of an Investigational New Drug (IND) package to the FDA. Bridge was noted to be preclinical contract research organization (CRO) that provides U.S.-level regulatory compliant drug development services globally.


Related Articles

  • Human microdosing; a boon or a bane? Seth, S. D.; Kumar, Nandini K.; Dua, Pradeep // Indian Journal of Medical Research;Aug2009, Vol. 130 Issue 2, p202 

    In this article the authors discuss human microdosing and its applications in drug development. Microdosing is a methodology developed in response to the United States Food and Drug Administration (USFDA) demands for new tools to make the drug development process less costly and more efficient....

  • Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Dieterle, Frank; Sistare, Frank; Goodsaid, Federico; Papaluca, Marisa; Ozer, Josef S.; Webb, Craig P.; Baer, William; Senagore, Anthony; Schipper, Matthew J.; Vonderscher, Jacky; Sultana, Stefan; Gerhold, David L.; Phillips, Jonathan A.; Maurer, Gérard; Carl, Kevin; Laurie, David; Harpur, Ernie; Sonee, Manisha; Ennulat, Daniela; Holder, Dan // Nature Biotechnology;May2010, Vol. 28 Issue 5, p455 

    The first formal qualification of safety biomarkers for regulatory decision making marks a milestone in the application of biomarkers to drug development. Following submission of drug toxicity studies and analyses of biomarker performance to the Food and Drug Administration (FDA) and European...

  • Workgroup Report: Review of Genomics Data Based on Experience with Mock Submissions -- View of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee. Leighton, John K.; Brown, Paul; Ellis, Amy; Harlow, Patricia; Harrouk, Wafa; Pine, P. Scott; Robison, Timothy; Rosario, Lilliam; Thompson2, Karol // Environmental Health Perspectives;Apr2006, Vol. 114 Issue 4, p573 

    Over the past few years, both the U.S. Food and Drug Administration (FDA) and the pharmaceutical industry have recognized the potential importance of pharmacogenomics and toxicogenomics to drug development. To resolve the uncertainties surrounding the use of microarray technology and the...

  • CytRx's ALS Drug Back to Clinic at Last.  // Bioworld Week;12/7/2009, Vol. 17 Issue 49, p5 

    The article reports that CytRx Corp. has had its restriction on molecular chaperone amplifier arimoclomol in amyotrophic lateral sclerosis lifted by the U.S. Food & Drug Administration. This enables the company to start its PhaseIIb clinical testing. The restriction was placed in January 2008 on...

  • Human Carcinogenic Risk Evaluation, Part III: Assessing Cancer Hazard and Risk in Human Drug Development. Jacobs, Abigail; Jacobson-Kram, David // Toxicological Sciences;Oct2004, Vol. 81 Issue 2, p260 

    Assessing cancer risk for human pharmaceuticals is important because drugs are taken at pharmacologically active doses and often on a chronic basis. Epidemiologic studies on patient populations have limited value because of the long latency period for most cancers and because these studies lack...

  • Warning! …Warning! Canavan, Neil // Drug Discovery & Development;Oct2007, Vol. 10 Issue 10, p34 

    The article focuses on the importance of the absorption, distribution, metabolism, and excretion (ADME) to toxicity testing in the U.S. It was claimed that the Food and Drug Administration (FDA) wants to measure tox performing in vitro assays in drug discovery instead of drug development....

  • Herbal medicine at a crossroads Taylor, David // Environmental Health Perspectives;Sep1996, Vol. 104 Issue 9, p924 

    No abstract available.

  • Pipeline preview.  // Formulary;Jul2008, Vol. 43 Issue 7, p234 

    This article lists drugs whose position in the U.S. Food and Drug Administration approval process changed in 2008 including the pneumonia drug Tigecycline, the osteoporosis drug Bazedoxifene, and the ulcerative colitis drug Balsalazide.

  • FDA blames industry for slow approvals.  // Medical Marketing & Media;Mar2001, Vol. 36 Issue 3, p34 

    Reports on the poor performance of Food and Drug Administration in approving developed drugs in the U.S. Delay in providing an approval letter; Factors contributing to the prolong of approval time; Review of products submitted by the pharmaceutical companies.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics